medigraphic.com

2021, Number 1

<< Back Next >>

Rev Cuba Endoc 2021; 32 (1)

Association among the hypertriglyceridemic waist phenotype, insulin resistance and the cardiometabolic variables in the polycystic ovary syndrome

Carmenate PJV, Cabrera RE, Monteagudo PG, Peix GA, González SR, González DN, Montes de Oca GP

Language: Spanish
References: 35
Page: 1-20
PDF size: 377.75 Kb.


ABSTRACT

Introduction: The polycystic ovary syndrome is frequently associated to cardiometabolic alterations; and its relation with the hypertriglyceridemic waist phenotype has been poorly studied in Cuba.
Objective: Identify the frequency of the hypertriglyceridemic waist phenotype in middle age women with polycystic ovary syndrome and its association with insulin resistance, disorders in the glucose metabolism and subclinical atherosclerosis.
Methods: Descriptive, cross-sectional study in 30 women. As clinical variables there were used: age, weight, size, body mass index, waist-hip circumference, waist/hip index, blood pressure; glucose, insulin, total cholesterol, triglycerides, HDL-c and LDL-c concentrations, and HOMA-IR index. Subclinical atherosclerosis was assessed by a carotid doppler and an echocardiogram (left ventricular hypertrophy and epicardial fat). The hypertriglyceridemic waist phenotype was defined as high triglycerides levels (≥ 1.7 mmol/L) and CC ≥ 80 cm.
Results: The frequency of the hypertriglyceridemic waist phenotype was 43.3% (13/30). The mean values of abdominal circumference, blood pressure, as well as glycemia (p < 0.003), insulinaemia (p = 0.028), triglycerides (p < 0.0001), and HOMA-IR index (p = 0.012) were higher in the group of women with that condition. Although there were not significant differences, the frequency of women with increase of the carotid intima-media thickness and epicardical fat was higher in those with the phenotype.
Conclusions: The presence of the hypertriglyceridemic waist phenotype is frequent in women with the polycystic ovary syndrome, and it is associated with alterations of the glucose metabolism and insulin resistance. This can be used in the clinical practice as a marker of risk for cardiometabolic alterations.


REFERENCES

  1. Sir Peterman T, Preisler J, Magendzo A. Síndrome de ovario poliquístico. Diagnóstico y manejo. Rev Med Clin Condes. 2013;24(5):818-26.

  2. Hernández J, Licea M. Relación entre la insulinorresistencia y el síndrome de ovario poliquístico y sus comorbilidades metabólicas. Rev Cubana Med Gen Integr. 2015;30:383-94.

  3. Papadakis G, Kandaraki EA, Tseniklidi E, Papalou O, Diamanti-Kandarakis E. Polycystic Ovary Syndrome and NC-CAH: Distinct Characteristics and Common Findings. A Systematic Review. Front Endocrinol (Lausanne). 2019 Jun 19;10:388. doi: 10.3389/fendo.2019.00388

  4. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.

  5. Fermín M, Pizzi R, Fung L, Curiel MA, Pérez Y, Centeno I, et al. Perfil lipídico en pacientes con síndrome de ovario poliquístico. Rev Venez Endocrinol Metab. 2016;14(3):187-95.

  6. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small, dense LDL) in men? Circulation. 2000;102:179-84.

  7. Morejón-Giraldoni A, Rivas-Alpízar E, Salas-García V, Benet-Rodríguez M. Prevalencia del fenotipo hipertrigliceridemia cintura abdominal alterada: resultados de la segunda medición de la iniciativa CARMEN. Revista Finlay [revista en Internet]. 2014 [citado: 28 marzo 2020];4(4). Disponible en: Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/article/view/321 .

  8. Linares-Reyes E, Castillo-Minaya K, Ríos-Mino M, Huamán-Saavedra J. Estudio de correlación entre los diagnósticos de cintura hipertrigliceridémica y síndrome metabólico en adultos de Trujillo, Perú. Rev Perú Med Exp Salud Pública. 2014;31(2):254-60.

  9. Ren Y, Liu Y, Sun X, Deng K, Wang C, Li L, et al. Hypertriglyceridemia-waist and risk of developing type 2 diabetes: The rural Chinese cohort study. Sci Rep. 2017[citado: 28 marzo 2020];7(1):9072. Disponible en: Disponible en: https://www.nature.com/articles/s41598-017-09136-x.pdf

  10. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Eleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-45.

  11. Diaz Díaz O, Hernández Rodriguez J, Domínguez Alonso E, Martínez Montenegro I, Bosch Pérez Y, del Busto Mesa A, et al. Valor de corte de la circunferencia de la cintura como predictor de disglucemia. Rev Cubana Endocrinol [Internet]. Abr 2017 [citado 3 Oct 2020];28(1):1-15. Disponible en: Disponible en: http://scielo.sld.cu/pdf/end/v28n1/end02117.pdf

  12. Arranz C, González RM, Álvarez A, Rodríguez B, Reyes A. Criterios de referencia para los indicadores de secreción de insulina y de los parámetros lipídicos en una población mixta hospitalaria. Rev Cubana Endocrinol. 2010;21(1):1-12.

  13. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-74.

  14. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organization 1999[citado 9 Nov 2020]. Disponible en: Disponible en: https://apps.who.int/iris/bitstream/handle/10665/66040/WHO_NCD_NCS_99.2.pdf?sequence=1&isAllowed=y

  15. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Part I: sex differences in traditional and novel risk factors, symptom evaluation and gender optimized diagnostic strategies. J Am Coll Cardiol. 2006;47(Suppl 3):S4-S20.

  16. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. Postmenopausal Women with a History of Irregular Menses and Elevated Androgen Measurements at High Risk for Worsening Cardiovascular Event- Free Survival: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metabol. 2008;93(4):1276-84.

  17. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab. 2002;87:2013-7.

  18. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at longterm follow-up. J Clin Epidemiol.1998;51:581-6.

  19. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod. 2001;16:556-60.

  20. Carvajal R, Herrera C, Porcile A. Espectro fenotípico del síndrome de ovario poliquístico. Rev Chil Obstet Ginecol. 2010;75(2):124-32.

  21. Jiménez M, Iturrieta V, Aguilera G, Cárcamo G, Gálvez Luis, Valdés P. Características clínicas y metabólicas de síndrome de ovario poliquístico en la ciudad de Temuco. Rev Chil Endocrinol Diabetes. 2014;7 (3):85-8.

  22. Sun Y, Wang W, Shen Q, Du S, Guo Y, He F, et al. Waist Circumference Coupled with Either HDL-C or TG Can Be Used as a Diagnostic Marker for Metabolic Syndrome in Chinese Women with Polycystic Ovary Syndrome. Int J Endocrinol. 2018 Sep 10;2018:6102085. doi: 10.1155/2018/6102085.

  23. Park SY, Cho YJ, Lee SR, Chung H, Jeong K. Triglyceride is a useful surrogate marker for insulin resistance in Korean women with polycystic ovary syndrome. Yonsei Med J. 2015;56(3):785-92.

  24. Lucas de Olivera V, Haas C, Wittke E, Marcadenti A. Hypertriglyceridemic waist (EWET), glycidic and lipid profile in patients with newly diagnosed heart attack. Nutr Hosp. 2015;32(3):1004-08.

  25. Kun Z, Shan-Shan Y, Hai-Bin W, Kang C, Zhao-Hui L, Yi-Ming M. Association between the hypertriglyceridemic waist phenotype and prediabetes in Chinese adults aged 40 years and older. Journal of Diabetes Research. 2018, Article ID 1031939, doi: https://doi.org/10.1155/2018/1031939

  26. Chen S, Guo X, Yu S, Sun G, Li Z, Sun Y. Association between the hypertriglyceridemic waist phenotype, prediabetes, and diabetes mellitus in rural Chinese population: A Cross-Sectional Study. Int J Environ Res Public Health[Internet]. 25 Mar 2016 [citado 2 Ago 2018 ];13(4):368. doi:10.3390/ijerph13040368.

  27. Janghorbani M, Amin M. Utility of hypertriglyceridemic waist phenotype for predicting incident type 2 diabetes: The Isfahan Diabetes Prevention Study. J Diabetes Investig. 2016;7(6):860-6.

  28. LeBlanc S, Coulombe F, Bertrand OF, Bibeau K, Pibarot P, Marette A, et al. Hypertriglyceridemic Waist: A Simple Marker of High-Risk Atherosclerosis Features Associated With Excess Visceral Adiposity/ Ectopic Fat. J Am Heart Assoc [Internet]. 2018 [cited 10, June 2020];7: e008139. DOI: 10.1161/JAHA.117.008139.

  29. Hernández Rodríguez J. La obesidad y la inflamación crónica de bajo grado. Rev Cubana Endocrinol [Internet]. Dic 2018 [citado 10 Nov 2020];29(3):1-3. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532018000300001&lng=es .

  30. Vaverková H, Karásek Y, Novotný M, Halenka J, Orság S. Hypertriglyceridemic waist a simple clinical tool to detect cardiometabolic risk: comparison with harmonized definition of metabolic syndrome physiol. Res. 2015;64(suppl. 3):s385-94.

  31. Tankó LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation. 2005;111(15):1883-90.

  32. Sam S, Haffner S, Davidson MH, D'Agostino RB Sr, Feinstein S, Kondos G, et al. Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. Diabetes Care. 2009;32(10):1916-20.

  33. Couto Alves A, Valcarcel B, Mäkinen V, Morin-Papunen L, Sebert S, Kangas AJ, et al. Metabolic profiling of polycystic ovary syndrome reveals interactions with abdominal obesity. Int J Obes (Lond) 2017;41(9):1331-40.

  34. Khan A, Karim N, Ainuddin JA, Fahim MF. Polycystic Ovarian Syndrome: Correlation between clinical hyperandrogenism, anthropometric, metabolic and endocrine parameters. Pak J Med Sci. 2019;35(5):1227-32.

  35. Carmenate Pérez J, Monteagudo Peña G, Peix González A, Quiroz Luis JJ, Ovies Carballo G, González Domínguez N. Enfermedad cardiovascular subclínica en mujeres de edad mediana con síndrome de ovario poliquístico. Rev Cubana Cardiol Cir Cardiovasc[Internet]. 2017 [citado 6 Feb 2019];23(1). Disponible en: Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/678




2020     |     www.medigraphic.com